Novartis completes agreement with Bayer Schering related to Betaseron rights and manufacturing

18-Sep-2007 - Novartis has completed an agreement with Bayer Schering Pharma AG (Bayer Schering) related to various rights for the multiple sclerosis treatment Betaseron® (interferon beta-1b) and has received a one-time payment of approximately USD 200 million. As part of the transaction, which was announced ...

Chiron Delivers FLUVIRIN(R) Influenza Virus Vaccine to U.S. Customer

First Shipments Mark Beginning of 2005-2006 FLUVIRIN Supply

19-Oct-2005 - Chiron Corporation announced that it has initiated the first delivery and release of FLUVIRIN(R) influenza virus vaccine to customers in the United States for the 2005-2006 influenza season. The company expects to continue to deliver shipments of FLUVIRIN vaccine throughout October and November ...

Chiron Responds to Novartis Offer

07-Sep-2005 - Chiron Corporation issued the following statement from Chiron's independent board directors in response to the offer from Novartis AG on September 1, 2005, to acquire the approximately 58% of Chiron shares that Novartis does not already own for $40 per Chiron share in cash: "Over the 10 years ...

Chiron Appoints Jack Goldstein President and Chief Operating Officer

25-Feb-2005 - Chiron Corporation announced the appointment of Jack Goldstein, 57, to the position of president and chief operating officer. Dr. Goldstein has served in this capacity on an interim basis since November 2004 and previously served as president of Chiron Blood Testing. As president and COO, Dr. ...

Abgenix Expands Antibody Agreements With Chiron,

02-Apr-2001 - Abgenix, Inc. (Nasdaq: ABGX) announced today that it has expanded its relationship with Chiron Corporation ("Chiron") (Nasdaq: CHIR). Under the new agreement, Chiron will use Abgenix’s XenoMouse ™ technology to generate fully human monoclonal antibody therapies against multiple cancer-specific ...

Abgenix Expands Antibody Agreements With Chiron

30-Mar-2001 - Abgenix, Inc. (Nasdaq: ABGX) announced today that it has expanded its relationship with Chiron Corporation ("Chiron") (Nasdaq: CHIR). Under the new agreement, Chiron will use Abgenix’s XenoMouse ™ technology to generate fully human monoclonal antibody therapies against multiple cancer-specific ...